Nippon Seika Co., Ltd.

Our company was established in 1918 as Nihon Kankou Co., Ltd. to unify the domestic camphor business.

Established Nihon Kankou Co., Ltd. in Kobe City.

Our company was established as Nihon Kankou Co., Ltd. to unify the domestic camphor business.

Established: February 1918 (Taisho 7).

Established Nihon Kankou Oil Sales Co., Ltd. (now Nissei Bairis Co., Ltd.).

Started manufacturing Japanese Pharmacopoeia camphor (Kankou): acquired factory site in Honjo Village, Muko District, Hyogo Prefecture (Honmatsu Factory, later Kobe Factory).

Established Nihon Kankou Chemical Industries Co., Ltd. in Honjo-cho, Higashinada-ku, Kobe City.

The headquarters and factory were completely destroyed by the Kobe air raid.

Inherited the operations of subsidiary Nihon Kankou Chemical Industries Co., Ltd. and started the fat and oil business (individual fatty acids, etc.).

Started manufacturing the lubricant 'Fatty Acid Monoamide (Neutron)' for polyolefin films.

Completed the headquarters building in Ubeai-ku (now Chuo-ku), Kobe City.

Established the Takasago plant in Takasago City, Hyogo Prefecture.

Changed the company name to Nippon Seika Co., Ltd.

We changed the company name to Nippon Seika Co., Ltd. and have been striving to develop products and expand business ahead of the needs of the times as a fine chemical manufacturer.

Moved the headquarters location to Osaka City.

Started manufacturing the toilet fragrance 'Picollet' at the Kobe plant.

Listed on the Second Section of the Osaka Stock Exchange.

Established a research institute within the Takasago plant.

Acquired the Environmental Health Biological Research Center Inc. (now Nissei Bairis Co., Ltd.).

Acquired Albous Pharmaceutical Co., Ltd. (now Albous Co., Ltd.).

Established the L Plant, a high-purity phospholipid manufacturing plant, at the Takasago plant.

Designated to the First Section of the Osaka Stock Exchange.

Merged with Yoshikawa Refining Co., Ltd. (now Kakogawa East Plant).

Established the FHP precision chemical manufacturing plant at Kakogawa East Plant; established a joint venture Sichuan Nippo Seika Co., Ltd. in China, and began manufacturing and selling fatty acid monoamide; obtained ISO9002 certification for fatty acid monoamide manufacturing at Takasago plant.

Started manufacturing cosmetic phospholipids at Kakogawa East Plant and listed on the First Section of the Tokyo Stock Exchange.

Obtained ISO9002 certification for cholesterol manufacturing at Kakogawa East Plant.

Expanded the L Plant to include a pharmaceutical pre-some manufacturing plant.

Obtained ISO14001 certification for Kakogawa East Plant; the pharmaceutical pre-some received GMP compliance approval from FDA and EMEA.

Obtained ISO14001 certification for Takasago Plant; started manufacturing functional oil additives at Takasago Plant.

Established the New MP clinical trial drug manufacturing plant at Takasago Plant.

Established the WJP distillation-only plant at Kakogawa East Plant.

Acquired Custom Serve Inc. (now Nissei Plastics Co., Ltd.).

Completed the relocation project of Sichuan Nippo Seika Co., Ltd., started operations at the new plant; established a joint venture 'Nirun Seika International Co., Ltd.' in Taiwan.

Started manufacturing plastic coating agents at Sichuan Nippo Seika Co., Ltd.

Established the FPC pharmaceutical and cosmetic raw material manufacturing plant at Kakogawa East Plant.

Established the LP2 pharmaceutical raw material manufacturing plant at Takasago Plant.

100th anniversary: 100th anniversary commemorative catalog (PDF: 5.66 MB).

Our company celebrated its 100th anniversary on February 12, 2018.

We celebrated our 100th anniversary.

In the mid-term management plan (five-year period 2018-2022) that began in April of the same year, under the slogan 'A corporate group that continues to grow toward a new 100 years', we listed on the Tokyo Stock Exchange Prime Market and have been working to strengthen corporate governance.

We launched the mid-term management plan (five-year period 2018-2022), listed on the Tokyo Stock Exchange Prime Market, and worked to strengthen corporate governance.

We formulated the long-term vision NFC VISION 2030, titled 'Making everyone smile with the power of Clean', and announced it in October 2021.

We formulated and announced the long-term vision NFC VISION 2030.

Transitioned to the Tokyo Stock Exchange Prime Market; established the NLP dedicated pharmaceutical phospholipid manufacturing plant at Takasago Plant; established the LP3 dedicated plant for Gilead Sciences at Takasago Plant; established the Lipid Office Building at Takasago Plant; Kobe Plant ceased operations.

Opened 'Shonan Lab' within Shonan Health Innovation Park; expanded ISO9001 application to all products except those that are GMP or GMP-compliant.

A new mid-term management plan (four-year period 2023-2026) has started.

Opened the Open Lab (The Design & Creation Lab.) on the first floor of the headquarters building.

Established the KSC office building at Kakogawa East Plant.